Last reviewed · How we verify

Recombinant EphB4-HSA Fusion Protein

AIDS Malignancy Consortium · Phase 2 active Biologic

Recombinant EphB4-HSA Fusion Protein is a Biologic drug developed by AIDS Malignancy Consortium. It is currently in Phase 2 development. Also known as: sEphB4-HSA.

At a glance

Generic nameRecombinant EphB4-HSA Fusion Protein
Also known assEphB4-HSA
SponsorAIDS Malignancy Consortium
ModalityBiologic
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Recombinant EphB4-HSA Fusion Protein

What is Recombinant EphB4-HSA Fusion Protein?

Recombinant EphB4-HSA Fusion Protein is a Biologic drug developed by AIDS Malignancy Consortium.

Who makes Recombinant EphB4-HSA Fusion Protein?

Recombinant EphB4-HSA Fusion Protein is developed by AIDS Malignancy Consortium (see full AIDS Malignancy Consortium pipeline at /company/aids-malignancy-consortium).

Is Recombinant EphB4-HSA Fusion Protein also known as anything else?

Recombinant EphB4-HSA Fusion Protein is also known as sEphB4-HSA.

What development phase is Recombinant EphB4-HSA Fusion Protein in?

Recombinant EphB4-HSA Fusion Protein is in Phase 2.

Related